Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330369
Status:
COMPLETED
Last Update Posted:
2014-03-18
First Post:
2006-05-24
Brief Title:
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
DORADO - A Phase 3 Randomized Double-Blind Placebo-Controlled Multi-Center Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs Including a Diuretic Protocol DAR-311
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a research study of a new experimental drug called darusentan Darusentan is not currently approved by the US Food and Drug Administration FDA for use in the United States which means that a doctor cannot prescribe this drug The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive drugs including a diuretic
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None